2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1310

Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy
Abstract Number: 2231

MCC22, a Novel Compound That Targets Both CCR5 and Mu Opioid Receptors, Is Highly Effective in Treating Inflammatory Arthritis Pain
Abstract Number: 800

Measurement of Serum Cytokines during the Apparent Remission State of Takayasu Arteritis – What Do Cytokines Tell Us?
Abstract Number: 2318

Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy
Abstract Number: 338

Measurement Properties of Paindetect, a Neuropathic Pain Screening Tool, for Evaluating Pain Phenotype in Patients with Rheumatoid Arthritis: Developing Neuropathic Pain Scale As a Measure of Treatment Outcome By Applying Rasch Analysis
Abstract Number: 2542

Measuring Psoriasis Specific Impact on Quality of Life: Performance of Dlqi and Skindex-17 in Early Psoriatic Arthritis
Abstract Number: 763

Mechanisms of Insulin-like Growth Factor-II-Mediated Fibrosis
Abstract Number: 2469

Median Time to Lda Is Shorter in Tocilizumab Combination Therapy with Csdmards As Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to Csdmards and/or TNF Inhibitors: Sub-Analysis of the Swiss and Austrian Patients from the ACT-SURE Study
Abstract Number: 2066

Mediation Analysis to Understand Genetic Relationships between Habitual Coffee Intake and Gout
Abstract Number: 449

Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Abstract Number: 1044

Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis
Abstract Number: 97

Medical Student Interest in Rheumatology As a Career
Abstract Number: 473

Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?
Abstract Number: 2783

Medications Associated with Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis
Abstract Number: 1403

Mediterranean Diet Is Inversely Associated with Risk of Rheumatoid Arthritis: A Swedish Population Based Case-Control Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].